Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Hoffmann

Showing results (41-50 of 113) with videos related to

Pageof 12
Sort By:
Molecular and Clinical Oncology|April 29, 2016
B3-lesions of the breast and cancer risk - an analysis of mammography screening patientsOliver Hoffmann, Gesina Athina Stamatis, Ann-Kathrin Bittner, et al.
Breast Cancer Research : BCR|August 12, 2009
Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cellsTanja Fehm, Oliver Hoffmann, Bahriye Aktas, et al.
Journal of Translational Medicine|May 5, 2016
Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroidsKathrin Halfter, Oliver Hoffmann, Nina Ditsch, et al.
Diagnostics (Basel, Switzerland)|February 25, 2022
Breast Radiation Exposure of 3D Digital Breast Tomosynthesis Compared to Full-Field Digital Mammography in a Clinical Follow-Up SettingMarcel Opitz, Sebastian Zensen, Katharina Breuckmann, et al.
Pain|March 7, 2019
Can a brief psychological expectancy intervention improve postoperative pain? A randomized, controlled trial in patients with breast cancerSven Benson, Susanne Hagen, Oliver Hoffmann, et al.
Journal of Cancer Research and Clinical Oncology|April 2, 2022
Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapseOliver Hoffmann, Sebastian Wormland, Ann-Kathrin Bittner, et al.
Anticancer Research|July 9, 2011
Circulating 20S proteasome in patients with non-metastasized breast cancerOliver Hoffmann, Martin Heubner, Timur Anlasik, et al.
BMC Cancer|February 6, 2019
Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancerLisa König, Fabian D Mairinger, Oliver Hoffmann, et al.
Breast Care (Basel, Switzerland)|September 26, 2022
The Role of C-Reactive Protein as a Prognostic Biomarker in Patients with Early Breast Cancer Treated with Neoadjuvant ChemotherapyAlexandra Edimiris-Herrmann, Cornelia Kolberg-Liedtke, Ann-Kathrin Bittner, et al.
Virology|May 3, 2011
Defining the human immunodeficiency virus type 1 transmission genetic bottleneck in a region with multiple circulating subtypes and recombinant formsAndile Nofemela, Gama Bandawe, Ruwayhida Thebus, et al.
Pageof 12

Showing results (41-50 of 113) with videos related to

Sort By:
Pageof 12
Molecular and Clinical Oncology|April 29, 2016
B3-lesions of the breast and cancer risk - an analysis of mammography screening patientsOliver Hoffmann, Gesina Athina Stamatis, Ann-Kathrin Bittner, et al.
Breast Cancer Research : BCR|August 12, 2009
Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cellsTanja Fehm, Oliver Hoffmann, Bahriye Aktas, et al.
Journal of Translational Medicine|May 5, 2016
Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroidsKathrin Halfter, Oliver Hoffmann, Nina Ditsch, et al.
Diagnostics (Basel, Switzerland)|February 25, 2022
Breast Radiation Exposure of 3D Digital Breast Tomosynthesis Compared to Full-Field Digital Mammography in a Clinical Follow-Up SettingMarcel Opitz, Sebastian Zensen, Katharina Breuckmann, et al.
Pain|March 7, 2019
Can a brief psychological expectancy intervention improve postoperative pain? A randomized, controlled trial in patients with breast cancerSven Benson, Susanne Hagen, Oliver Hoffmann, et al.
Journal of Cancer Research and Clinical Oncology|April 2, 2022
Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapseOliver Hoffmann, Sebastian Wormland, Ann-Kathrin Bittner, et al.
Anticancer Research|July 9, 2011
Circulating 20S proteasome in patients with non-metastasized breast cancerOliver Hoffmann, Martin Heubner, Timur Anlasik, et al.
BMC Cancer|February 6, 2019
Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancerLisa König, Fabian D Mairinger, Oliver Hoffmann, et al.
Breast Care (Basel, Switzerland)|September 26, 2022
The Role of C-Reactive Protein as a Prognostic Biomarker in Patients with Early Breast Cancer Treated with Neoadjuvant ChemotherapyAlexandra Edimiris-Herrmann, Cornelia Kolberg-Liedtke, Ann-Kathrin Bittner, et al.
Virology|May 3, 2011
Defining the human immunodeficiency virus type 1 transmission genetic bottleneck in a region with multiple circulating subtypes and recombinant formsAndile Nofemela, Gama Bandawe, Ruwayhida Thebus, et al.
Pageof 12